IHCeasy PPARG Ready-To-Use IHC Kit
PPARG Ready-to-use reagent kit for IHC.
Cat no : KHC0249
Synonyms
CIMT1, NR1C3, PPAR gamma, PPARG, PPARG1, PPARG2, PPARgamma, PPARγ
Validation Data Gallery
Product Information
KHC0249 is a ready-to-use IHC kit for staining of PPARG. The kit provides all reagents, from antigen retrieval to cover slip mounting, that require little to no diluting or handling prior to use. Simply apply the reagents to your sample slide according to the protocol and you're steps away from obtaining high-quality IHC data.
Product name | IHCeasy PPARG Ready-To-Use IHC Kit |
Sample type | FFPE tissue |
Assay type | Immunohistochemistry |
Primary antibody type | Rabbit Polyclonal |
Secondary antibody type | Polymer-HRP-Goat anti-Rabbit |
Reactivity | Human, Rat |
Kit components
Component | Size | Concentration |
---|---|---|
Antigen Retrieval Buffer | 100 mL | 50× |
Washing Buffer | 100 mL ×2 | 20× |
Blocking Buffer | 5 mL | RTU |
Primary Antibody | 5 mL | RTU |
Secondary Antibody | 5 mL | RTU |
Chromogen Component A | 0.2 mL | RTU |
Chromogen Component B | 4 mL | RTU |
Signal Enhancer | 5 mL | RTU |
Counter Staining Reagent | 5 mL | RTU |
Mounting Media | 5 mL | RTU |
Datasheet | 1 Copy | |
Manual | 1 Copy |
Background Information
Peroxisome Proliferator-Activated Receptors (PPARs) are ligand-activated intracellular transcription factors, members of the nuclear hormone receptor superfamily (NR), that includes estrogen, thyroid hormone receptors, retinoic acid, Vitamin D3 as well as retinoid X receptors (RXRs). The PPAR subfamily consists of three subtypes encoded by distinct genes denoted PPARα (NR1C1), PPARβ/δ (NR1C2) and PPARγ (NR1C3), which are activated by selective ligands. PPARγ, also named as PPARG, contains one nuclear receptor DNA-binding domain and is a receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. It plays an important role in the regulation of lipid homeostasis, adipogenesis, INS resistance, and development of various organs. Defects in PPARG are the cause of familial partial lipodystrophy type 3 (FPLD3) and may be associated with susceptibility to obesity. Defects in PPARG can lead to type 2 INS-resistant diabetes and hypertension. PPARG mutations may be associated with colon cancer. Genetic variations in PPARG are associated with susceptibility to glioma type 1 (GLM1). PPARG has been reported to be localized mainly (but not always) in the nucleus. PPARG can also be detected in the cytoplasm and was reported to possess extra-nuclear/non-genomic actions.
Properties
Storage Instructions | All the reagents are stored at 2-8°C. The kit is stable for 6 months from the date of receipt. |
Synonyms | CIMT1, NR1C3, PPAR gamma, PPARG, PPARG1, PPARG2, PPARgamma, PPARγ |